Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus

Jill E. Koshiol, Jane C. Schroeder, Denise J. Jamieson, Stephen W. Marshall, Ann Duerr, Charles M. Heilig, Keerti V. Shah, Robert S. Klein, Susan Cu-Uvin, Paula Schuman, David D Celentano, Jennifer S. Smith

Research output: Contribution to journalArticle

Abstract

Persistent infection with high-risk human papillomavirus (HPV) is central to cervical carcinogenesis. Certain high-risk types, such as HPV16, may be more persistent than other HPV types, and type-specific HPV persistence may differ by HIV serostatus. This study evaluated the association between HPV type and clearance of HPV infections in 522 HIV-seropositive and 279 HIV-seronegative participants in the HIV Epidemiology Research Study (HERS, United States, 1993-2000). Type-specific HPV infections were detected using MY09/MY11/HMB01-based PCR and 26 HPV type-specific probes. The estimated duration of type-specific infections was measured from the first HPV-positive visit to the first of two consecutive negative visits. Hazard ratios (HRs) and 95% confidence intervals (CIs) for HPV clearance were calculated using Cox models adjusted for study site and risk behavior (sexual or injection drugs). A total of 1,800 HPV infections were detected in 801 women with 4.4 years median follow-up. HRs for clearance of HPV16 and related types versus low-risk HPV types were 0.79 (95% CI: 0.64-0.97) in HIV-positive women and 0.86 (95% CI: 0.59-1.27) in HIV-negative women. HRs for HPV18 versus low-risk types were 0.80 (95% CI: 0.56-1.16) and 0.57 (95% CI: 0.22-1.45) for HIV-positive and -negative women, respectively. HPV types within the high-risk category had low estimated clearance rates relative to low-risk types, but HRs were not substantially modified by HIV serostatus.

Original languageEnglish (US)
Pages (from-to)1623-1629
Number of pages7
JournalInternational Journal of Cancer
Volume119
Issue number7
DOIs
StatePublished - Oct 1 2006

Fingerprint

Papillomavirus Infections
HIV
Confidence Intervals
Risk-Taking
Infection
Proportional Hazards Models
Carcinogenesis
Epidemiology
Odds Ratio

Keywords

  • HIV
  • HPV type
  • Human
  • Papillomavirus
  • Time to clearance

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Koshiol, J. E., Schroeder, J. C., Jamieson, D. J., Marshall, S. W., Duerr, A., Heilig, C. M., ... Smith, J. S. (2006). Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus. International Journal of Cancer, 119(7), 1623-1629. https://doi.org/10.1002/ijc.22015

Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus. / Koshiol, Jill E.; Schroeder, Jane C.; Jamieson, Denise J.; Marshall, Stephen W.; Duerr, Ann; Heilig, Charles M.; Shah, Keerti V.; Klein, Robert S.; Cu-Uvin, Susan; Schuman, Paula; Celentano, David D; Smith, Jennifer S.

In: International Journal of Cancer, Vol. 119, No. 7, 01.10.2006, p. 1623-1629.

Research output: Contribution to journalArticle

Koshiol, JE, Schroeder, JC, Jamieson, DJ, Marshall, SW, Duerr, A, Heilig, CM, Shah, KV, Klein, RS, Cu-Uvin, S, Schuman, P, Celentano, DD & Smith, JS 2006, 'Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus', International Journal of Cancer, vol. 119, no. 7, pp. 1623-1629. https://doi.org/10.1002/ijc.22015
Koshiol, Jill E. ; Schroeder, Jane C. ; Jamieson, Denise J. ; Marshall, Stephen W. ; Duerr, Ann ; Heilig, Charles M. ; Shah, Keerti V. ; Klein, Robert S. ; Cu-Uvin, Susan ; Schuman, Paula ; Celentano, David D ; Smith, Jennifer S. / Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus. In: International Journal of Cancer. 2006 ; Vol. 119, No. 7. pp. 1623-1629.
@article{43831082fdde4a3ba2513ebca2fcc795,
title = "Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus",
abstract = "Persistent infection with high-risk human papillomavirus (HPV) is central to cervical carcinogenesis. Certain high-risk types, such as HPV16, may be more persistent than other HPV types, and type-specific HPV persistence may differ by HIV serostatus. This study evaluated the association between HPV type and clearance of HPV infections in 522 HIV-seropositive and 279 HIV-seronegative participants in the HIV Epidemiology Research Study (HERS, United States, 1993-2000). Type-specific HPV infections were detected using MY09/MY11/HMB01-based PCR and 26 HPV type-specific probes. The estimated duration of type-specific infections was measured from the first HPV-positive visit to the first of two consecutive negative visits. Hazard ratios (HRs) and 95{\%} confidence intervals (CIs) for HPV clearance were calculated using Cox models adjusted for study site and risk behavior (sexual or injection drugs). A total of 1,800 HPV infections were detected in 801 women with 4.4 years median follow-up. HRs for clearance of HPV16 and related types versus low-risk HPV types were 0.79 (95{\%} CI: 0.64-0.97) in HIV-positive women and 0.86 (95{\%} CI: 0.59-1.27) in HIV-negative women. HRs for HPV18 versus low-risk types were 0.80 (95{\%} CI: 0.56-1.16) and 0.57 (95{\%} CI: 0.22-1.45) for HIV-positive and -negative women, respectively. HPV types within the high-risk category had low estimated clearance rates relative to low-risk types, but HRs were not substantially modified by HIV serostatus.",
keywords = "HIV, HPV type, Human, Papillomavirus, Time to clearance",
author = "Koshiol, {Jill E.} and Schroeder, {Jane C.} and Jamieson, {Denise J.} and Marshall, {Stephen W.} and Ann Duerr and Heilig, {Charles M.} and Shah, {Keerti V.} and Klein, {Robert S.} and Susan Cu-Uvin and Paula Schuman and Celentano, {David D} and Smith, {Jennifer S.}",
year = "2006",
month = "10",
day = "1",
doi = "10.1002/ijc.22015",
language = "English (US)",
volume = "119",
pages = "1623--1629",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus

AU - Koshiol, Jill E.

AU - Schroeder, Jane C.

AU - Jamieson, Denise J.

AU - Marshall, Stephen W.

AU - Duerr, Ann

AU - Heilig, Charles M.

AU - Shah, Keerti V.

AU - Klein, Robert S.

AU - Cu-Uvin, Susan

AU - Schuman, Paula

AU - Celentano, David D

AU - Smith, Jennifer S.

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Persistent infection with high-risk human papillomavirus (HPV) is central to cervical carcinogenesis. Certain high-risk types, such as HPV16, may be more persistent than other HPV types, and type-specific HPV persistence may differ by HIV serostatus. This study evaluated the association between HPV type and clearance of HPV infections in 522 HIV-seropositive and 279 HIV-seronegative participants in the HIV Epidemiology Research Study (HERS, United States, 1993-2000). Type-specific HPV infections were detected using MY09/MY11/HMB01-based PCR and 26 HPV type-specific probes. The estimated duration of type-specific infections was measured from the first HPV-positive visit to the first of two consecutive negative visits. Hazard ratios (HRs) and 95% confidence intervals (CIs) for HPV clearance were calculated using Cox models adjusted for study site and risk behavior (sexual or injection drugs). A total of 1,800 HPV infections were detected in 801 women with 4.4 years median follow-up. HRs for clearance of HPV16 and related types versus low-risk HPV types were 0.79 (95% CI: 0.64-0.97) in HIV-positive women and 0.86 (95% CI: 0.59-1.27) in HIV-negative women. HRs for HPV18 versus low-risk types were 0.80 (95% CI: 0.56-1.16) and 0.57 (95% CI: 0.22-1.45) for HIV-positive and -negative women, respectively. HPV types within the high-risk category had low estimated clearance rates relative to low-risk types, but HRs were not substantially modified by HIV serostatus.

AB - Persistent infection with high-risk human papillomavirus (HPV) is central to cervical carcinogenesis. Certain high-risk types, such as HPV16, may be more persistent than other HPV types, and type-specific HPV persistence may differ by HIV serostatus. This study evaluated the association between HPV type and clearance of HPV infections in 522 HIV-seropositive and 279 HIV-seronegative participants in the HIV Epidemiology Research Study (HERS, United States, 1993-2000). Type-specific HPV infections were detected using MY09/MY11/HMB01-based PCR and 26 HPV type-specific probes. The estimated duration of type-specific infections was measured from the first HPV-positive visit to the first of two consecutive negative visits. Hazard ratios (HRs) and 95% confidence intervals (CIs) for HPV clearance were calculated using Cox models adjusted for study site and risk behavior (sexual or injection drugs). A total of 1,800 HPV infections were detected in 801 women with 4.4 years median follow-up. HRs for clearance of HPV16 and related types versus low-risk HPV types were 0.79 (95% CI: 0.64-0.97) in HIV-positive women and 0.86 (95% CI: 0.59-1.27) in HIV-negative women. HRs for HPV18 versus low-risk types were 0.80 (95% CI: 0.56-1.16) and 0.57 (95% CI: 0.22-1.45) for HIV-positive and -negative women, respectively. HPV types within the high-risk category had low estimated clearance rates relative to low-risk types, but HRs were not substantially modified by HIV serostatus.

KW - HIV

KW - HPV type

KW - Human

KW - Papillomavirus

KW - Time to clearance

UR - http://www.scopus.com/inward/record.url?scp=33747506113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747506113&partnerID=8YFLogxK

U2 - 10.1002/ijc.22015

DO - 10.1002/ijc.22015

M3 - Article

C2 - 16646070

AN - SCOPUS:33747506113

VL - 119

SP - 1623

EP - 1629

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 7

ER -